| One-year Outcome of Intravitreal Dexamethasone Implant for Macular Edema Secondary to Central Retinal Vein Occlusion. |
|
Tae Hoon Kim, Chang Ki Yoon, Ji Eun Lee, Joo Eun Lee, In Young Chung, Min Sagong, Kun Hyung Kim, Hyun Woong Kim |
1Department of Ophthalmology, Busan Paik Hospital, Inje University College of Medicine, Busan, Korea. maekbak@hanmail.net
2Department of Ophthalmology, Pusan National University School of Medicine, Yangsan, Korea.
3Department of Ophthalmology, Haeundae Paik Hospital, Inje University College of Medicine, Busan, Korea.
4Department of Ophthalmology, Gyeongsang National University School of Medicine, Jinju, Korea.
5Department of Ophthalmology, Yeungnam University College of Medicine, Daegu, Korea.
6Institute of Environmental and Occupational Medicine, Department of Occupational and Environmental Medicine, Inje University College of Medicine, Busan, Korea. |
| 망막중심정맥폐쇄에 동반된 황반부종에서 유리체강내 덱사메타손삽입물 치료의 1년 효과 |
|
김태훈1⋅윤창기1⋅이지은2⋅이주은3⋅정인영4⋅사공민5⋅김건형6⋅김현웅1 |
|
인제대학교 의과대학 부산백병원 안과학교실1, 부산대학교 의과대학 안과학교실2, 인제대학교 의과대학 해운대백병원 안과학교실3, 경상대학교 의학전문대학원 안과학교실4, 영남대학교 의과대학 안과학교실5, 인제대학교 의과대학 직업환경의학교실 및 환경⋅산업의학연구소6 |
|
|
| Abstract |
PURPOSE
In the present study, 1-year outcome of intravitreal dexamethasone implant in macular edema secondary to central retinal vein occlusion (CRVO) was evaluated. METHODS: The medical records of 22 patients (22 eyes) with macular edema secondary to CRVO were reviewed retrospectively. All patients were treated with intravitreal dexamethasone implant more than twice a year and followed up at least for 1 year from the first dexamethasone implant injection. The best-corrected visual acuity (BCVA), central macular thickness (CMT), and intraocular pressure (IOP) were measured every 2 months after the first injection. Adverse effects, including cataract formation and elevation of IOP, were analyzed. RESULTS: The mean patient age was 64.3 ± 9.5 years and 10 patients (45.5%) were male. The average number of injections was 2.4 ± 0.6 and the interval between the first and second injection was 22.0 ± 6.4 weeks. The mean BCVA (log MAR) was 0.82 ± 0.50 and 0.72 ± 0.62 at baseline and after 1 year, respectively. Vision was significantly improved for 8 months after the first injection (p < 0.05). However, vision was not different from baseline after 1 year. The CMT was significantly decreased compared to baseline (p < 0.001). Subgroup analysis revealed that BCVA was improved and CMT decreased significantly when intravitreal dexamethasone concentration was presumed sufficient. Moreover, CMT decreased significantly in hypertensive and ischemic groups compared with normotensive and non-ischemic groups, respectively (p < 0.001). Elevated IOP was observed in 6 eyes (27.3%), but all 6 eyes became normal after topical agent was applied. Cataract formation was observed in 3 eyes (13.6%). CONCLUSIONS: Intravitreal dexamethasone implant resulted in visual acuity stabilization and macular edema reduction in patients having macular edema secondary to CRVO without significant adverse events. |
| Key Words:
Central retinal vein occlusion;Dexamethasone implant;Macular edema;Ozurdex |
|
PDF Links
Full text via DOI
Download Citation
